Aims
SARS-CoV-2 infection may lead to endothelial and vascular dysfunction. We investigated alterations of arterial stiffness, endothelial coronary and myocardial function markers 4 months after COVID-19 infection.
Methods and results
In a case-control prospective study, we included 70 patients 4 months after COVID-19 infection, 70 age- and sex-matched untreated hypertensive patients (positive control) and 70 healthy individuals. We measured (i) perfused boundary region (PBR) of the sublingual arterial microvessels (increased PBR indicates reduced endothelial glycocalyx thickness), (ii) flow-mediated dilatation (FMD), (iii) coronary flow reserve (CFR) by Doppler echocardiography, (iv) pulse wave velocity (PWV), (v) global left and right ventricular longitudinal strain (GLS), and (vi) malondialdehyde (MDA), an oxidative stress marker, thrombomodulin and von Willebrand factor as endothelial biomarkers. COVID-19 patients had similar CFR and FMD as hypertensives (2.48βΒ±β0.41 vs. 2.58βΒ±β0.88, P = 0.562, and 5.86βΒ±β2.82% vs. 5.80βΒ±β2.07%, P = 0.872, respectively) but lower values than controls (3.42βΒ±β0.65, P = 0.0135, and 9.06βΒ±β2.11%, P = 0.002, respectively). Compared to controls, both COVID-19 and hypertensives had greater PBR5β25 (2.07βΒ±β0.15βΒ΅m and 2.07βΒ±β0.26βΒ΅m, P = 0.8 vs. 1.89βΒ±β0.17βΒ΅m, P = 0.001), higher PWV (carotidβfemoral PWV 12.09βΒ±β2.50 vs. 11.92βΒ±β2.94, P = 0.7 vs. 10.04βΒ±β1.80βm/s, P = 0.036) and impaired left and right ventricular GLS (β19.50βΒ±β2.56% vs. β19.23βΒ±β2.67%, P = 0.864 vs. β21.98βΒ±β1.51%, P = 0.020 and β16.99βΒ±β3.17% vs. β18.63βΒ±β3.20%, P = 0.002 vs. β20.51βΒ±β2.28%, Pβ<β0.001). MDA and thrombomodulin were higher in COVID-19 patients than both hypertensives and controls (10.67βΒ±β0.32 vs 1.76βΒ±β0.03, P = 0.003 vs. 1.01βΒ±β0.05βnmol/L, P = 0.001 and 3716.63βΒ±β188.36 vs. 3114.46βΒ±β179.18βpg/mL, P = 0.017 vs. 2590.02βΒ±β156.51βpg/mL, Pβ<β0.001). Residual cardiovascular symptoms at 4 months were associated with oxidative stress and endothelial dysfunction markers.
Conclusions
SARS-CoV-2 may cause endothelial and vascular dysfunction linked to impaired cardiac performance 4 months after infection.
NuLife Sciences, Inc.
7407 Ziegler Rd
Chattanooga, TN 37421
(800) 398-9842